On February 11, 2013, Steve Usdin, Washington Editor of BioCentury, published an article in BioCentury The Bernstein Report on Business focused on the future of the FDA’s Division of Neurology Products following the expected retirement later this year of the current Division Director, Russell Katz, M.D. Representatives from the biopharmaceutical industry and the patient advocacy community were interviewed for this article, including Daniel Perry, President & CEO of the Alliance for Aging research and Chair of the ACT-AD Coalition. Mr. Perry highlighted ACT-AD’s positive relationship with Dr. Katz and expressed hope that Dr. Katz’s successor will approach the review of therapies for Alzheimer’s disease with similar openness and flexibility.

To read the BioCentury article, click here.